Drugs / αDC1 Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07634094 | Aug 2026 → Aug 2028 expected | ovarian cancer | Kalinski, Pawel, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02615574 | Mar 2016 → Jun 2018 | colorectal cancer | Pawel Kalinski | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | αDC1 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02615574 ↗ |
| Known as | Type-1 Polarized Dendritic Cell (αDC1) Vaccine | “A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects...” NCT02615574 ↗ |
| Modality | Vaccine | “Autologous tumor-loaded alpha-DC1 vaccine” NCT07634094 ↗ |
| Route | Other | “ID injection on rotating sides of lower extremities” NCT07634094 ↗ |